
Inhibikase Therapeutics Inc
NASDAQ:IKT

Intrinsic Value
The intrinsic value of one
IKT
stock under the Base Case scenario is
1.25
USD.
Compared to the current market price of 1.98 USD,
Inhibikase Therapeutics Inc
is
Overvalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Inhibikase Therapeutics Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Inhibikase Therapeutics Inc
Balance Sheet Decomposition
Inhibikase Therapeutics Inc
Current Assets | 94.2m |
Cash & Short-Term Investments | 93.2m |
Other Current Assets | 984.5k |
Non-Current Assets | 116.5k |
PP&E | 116.6k |
Other Non-Current Assets | -100 |
Free Cash Flow Analysis
Inhibikase Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Inhibikase Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-38.4m
USD
|
Operating Income
|
-38.4m
USD
|
Other Expenses
|
1.9m
USD
|
Net Income
|
-36.5m
USD
|
IKT Profitability Score
Profitability Due Diligence
Inhibikase Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Score
Inhibikase Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
IKT Solvency Score
Solvency Due Diligence
Inhibikase Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Inhibikase Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IKT Price Targets Summary
Inhibikase Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
IKT
is 8.16 USD
with a low forecast of 8.08 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for IKT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IKT
stock under the Base Case scenario is
1.25
USD.
Compared to the current market price of 1.98 USD,
Inhibikase Therapeutics Inc
is
Overvalued by 37%.